Original Articles: Allergen-Specific Immunotherapy and Biologics
To add the references below to your reference management program: 1. Download the file; 2. Open your reference management program or EndNote; 3. Select File and import |
87 Articles |
-
Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies
Pfaar, O., Devillier, P., Schmitt, J., et al. Allergy. First published: 27 March 2023
-
Immune Response Evolution in Peanut Epicutaneous Immunotherapy for Peanut-Allergic Children
Bastin, M., Carr, W.W., Davis, C.M., et al. Allergy. First published: 14 March 2023
-
The next generation virus-like particle platform for the treatment of peanut allergy
Sobczak, J.M., Krenger, P.S., Storni, F., et al. Allergy. First published: 08 March 2023
-
Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice
Paolucci, M., Wuillemin, N., Homère, V., et al. Allergy. First published: 27 January 2023
-
Anti-kit antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria
Terhorst-Molawi, D., Hawro, T., Grekowitz, E., et al. Allergy. First published: 16 November 2022
-
Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment
Heeb, LEM, Boyman, O. Allergy. First published: 05 November 2022
-
Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation
Benito-Villalvilla, C., de la Rocha-Muñoz, A., López-Abente, J., et al. Allergy. First published: 31 October 2022
-
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
Renert-Yuval, Y., Pavel, A.B., Del Duca, E., et al. Allergy. First published: 22 October 2022
-
Stimulation of naïve B cells with a fusion protein consisting of FlaA and Bet v 1 induces regulatory B cells ex vivo
Goretzki, A., Lin, Y.-J., Meier, C., et al. Allergy. First published: 04 October 2022
-
Efficacy and safety of food allergy oral immunotherapy in adults
Epstein-Rigbi, N., Levy, M.B., Nachshon, L., et al. Allergy. First published: 03 October 2022
-
Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis
Soyka, M.B., Ryser, F.S., Brühlmann, C., et al. Allergy. First published: 26 September 2022
-
RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: two unique cell fates and CD29 as a biomarker for treatment effect
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. First published: 25 September 2022
-
Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children
Kauppila, TK, Hinkkanen, V, Savinko, T, et al. Allergy. First published: 15 August 2022
-
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma
Papi, A., Corren, J., Castro, M., et al. Allergy. First published: 28 July 2022
-
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Spekhorst, L.S., Bakker, D., Drylewicz, J., et al. Allergy. First published: 15 July 2022
-
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis
Fokkens, W.J., Mullol, J., Kennedy, D., et al. Allergy. First published: 13 July 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis
Berdyshev, E., Goleva, E., Bissonnette, R., et al. Allergy. First published: 11 July 2022
A recombinant multimeric dog allergen prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses
Stark, J.M., Liu, J., Tibbitt, C.A., et al. Allergy. First published: 03 June 2022
Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks
Ashley, SE, Jones, AC, Anderson, D, et al. Allergy. First published: 27 May 2022
First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
Nieto, A., Mazón, Á., Nieto, M., et al. Allergy. First published: 16 May 2022
Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference
Sousa-Pinto, B., Schünemann, H.J., Sá-Sousa, A., et al. Allergy. First published: 14 May 2022
Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma
Farraia, M., Paciência, I., Mendes, F.C., et al. Allergy. First published: 22 April 2022
Psychometric parameters of food allergy quality of life during an allergen immunotherapy trial
Lins de Holanda Coelho, G., DunnGalvin, A., Greenhawt, M., et al. Allergy. First published: 25 April 2022
Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens
Potapova, E., Bordas-Le Floch, V., Schlederer, T., et al. Allergy. First published: 26 April 2022
Allergen Immunotherapy for asthma prevention: a systematic review and meta-analysis of randomised and non-randomised controlled studies
Farraia, M., Paciência, I., Mendes, F.C., et al. Allergy. First published: 28 March 2022
The anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study
Alvarado, D., Maurer, M., Gedrich, R., et al. Allergy. First published: 19 February 2022
Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps
Lee, S.E., Hopkins, C., Mullol, J. et al. Allergy. First published: 16 January 2022
A phase 2, randomized multi oral immunotherapy with omalizumab ‘real life’ study
Sindher, S.B., Kumar, D., Cao, S., et al. Allergy. First published: 11 January 2022
Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (Nut CRACKER study)
Elizur, A., Appel, M.Y., Nachshon, L., et al. Allergy. First published: 09 January 2022
Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: systematic review and meta-analysis
de Silva, D., Rodríguez del Río, P., de Jong, N.W., et al. Allergy. First published: 09 January 2022
Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy
Blaiss, M.S., Juhl, R.G., Siew, L.Q., et al. Allergy. First published: 05 January 2022
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
Corren, J., Pham, T.-H., Gil, E.G., et al. Allergy. First published: 16 December 2021
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study
Maurer, M, Giménez-Arnau, A, Bernstein, JA, et al. Allergy. First published: 13 November 2021
A three-stage design for allergen immunotherapy trials
Tang, X., Rabin, R.L., Yan, L.K. Allergy. First published: 02 October 2021
Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae
Zhou, Y., Li, Q., Pan, R., et al. Allergy. First published: 27 September 2021
Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy
Bordas-Le Floch, V, Berjont, N, Batard, T, et al. Allergy. First published: 22 September 2021
Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection
Yilmaz, IC, Ipekoglu, EM, Bulbul, A, et al. Allergy. First published: 14 September 2021
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients
Guttman-Yassky, E, Renert-Yuval, Y, Bares, J, et al. Allergy. First published: 30 August 2021
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials
Mullol, J., Laidlaw, T.M., Bachert, C., et al. Allergy. First published: 30 August 2021
High dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase
Hellkvist, L, Hjalmarsson, E, Weinfeld, D, et al. Allergy. First published: 11 August 2021
Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study
Banerji, A., Bernstein, J.A., Johnston, D.T., et al. Allergy. First published: 21 July 2021
Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy
Heldner, A., Alessandrini, F., Russkamp, D., et al. Allergy. First published: 20 July 2021
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status
Fujieda, S, Matsune, S, Takeno, S, et al.Allergy. First published: 16 May 2021
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis
Canonica, G.W., Harrison, T.W., Chanez, P., et al. Allergy. First published: 12 May 2021
Standardisation of allergen products: 4. Validation of a candidate European pharmacopoeia standard method for quantification of major grass pollen allergen Phl p 5
Wang, S.-H., Zissler, U.M., Buettner, M., et al. Allergy. First published: 09 May 2021
RNA viruses in the house dust mite dermatophagoidespteronyssinus, detection in environmental samples and in commercial allergen extracts used for in vivo diagnosis
Vidal-Quist, J.C., Vidal, C., Escolar, F., Lambrecht, B.N., Rombauts, S. and Hernández-Crespo, P.Allergy. First published: 29 April 2021
Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials
Biedermann, T., Couroux, P., Greve, T.M. and Mäkelä, M. Allergy. First published: 27 April 2021
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis
Miyano, T., Irvine, A.D. and Tanaka, R.J. Allergy.First published: 24 April 2021
Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic
Yeğit, O.O., Demir, S., Ünal, D., et al. Allergy. First published: 27 April 2021
An exhausted phenotype of TH2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy
Wang, S.-H., Zissler, U.M., Buettner, M., et al. Allergy. 2021; 76: 2827-2839
Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab
Manohar, M., Dunham, D., Gupta, S., et al. Allergy. 2021; 76: 2809-2826
Low-affinity but high-avidity interactions may offer an explanation for IgE-mediated allergen cross-reactivity
Chang, X, Zha, L, Wallimann, A, et al. Allergy. 2021; 76: 2565– 2574
IgE-cross-blocking antibodies to fagales following sublingual immunotherapy with recombinant Bet v 1
Grilo, J.R., Kitzmüller, C., Aglas, et al. Allergy.2021; 76: 2555-2564
Allergen-specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways
Zissler, U.M., Jakwerth, C.A., Guerth, F., et al. Allergy.2021; 76: 2461-2474
β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy
Sturm, G.J., Herzog, S.A., Aberer, W., et al. Allergy.2021; 76: 2166-2176
Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant
Leonard, C., Montamat, G., Davril, C., et al. Allergy.2021; 76: 2153-2165
Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial
Lou, H, Huang, Y, Ouyang, Y, et al. Allergy. 2020; 75: 2026– 2036
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Ohsawa, I., Honda, D., Suzuki, Y., Allergy.2021; 76: 1789-1799
Exercise-induced allergic reactions on desensitization to wheat after rush oral immunotherapy
Furuta, T, Tanaka, K, Tagami, K, et al. Allergy. 2020; 75: 1414– 1422
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis
Pelletier, B, Perrin, A, Assoun, N, et al. Allergy. 2021; 76: 1213– 1222
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics
Barker-Tejeda, TC, Bazire, R, Obeso, D, et al. Allergy. 2021; 76: 1199– 1212
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study
Lumry, W.R., Weller, K., Magerl, M., et al. Allergy.2021; 76: 1188-1198
Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma
Korotchenko, E, Schießl, V, Scheiblhofer, S, et al. Allergy. 2021; 76: 210– 222
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline
Bourdin, A, Papi, AA, Corren, J, et al. Allergy. 2021; 76: 269– 280
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
Riedl, MA, Maurer, M, Bernstein, JA, et al. Allergy. 2020; 75: 2879– 2887
Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
Nettis, E, Patella, V, Lombardo, C, et al. Allergy. 2020; 75: 2653– 2661
Quality of life of children aged 8-12 years undergoing food allergy oral immunotherapy: Child and parent perspective
Epstein-Rigbi, N, Goldberg, MR, Levy, MB, Nachshon, L, Elizur, A. et al. Allergy. 2020; 75: 2623– 2632
Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma
Jutel, M, Brüggenjürgen, B, Richter, H, Vogelberg, C. Allergy. 2020; 75: 2050– 2058
Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy
Jensen, RK, Jabs, F, Miehe, M, et al. Allergy. 2020; 75: 1956– 1965
Laser-facilitated epicutaneous immunotherapy with depigmented house dust mite extract alleviates allergic responses in a mouse model of allergic lung inflammation
Korotchenko, E, Moya, R, Scheiblhofer, S, et al.Allergy. 2020; 75: 1217– 1228
CARsomes inhibit airway allergic inflammation in mice by inducing antigen-specific Th2 cell apoptosis
Zhang, H-P, Sun, Y-X, Lin, Z, et al. Allergy. 2020; 75: 1205– 1216
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Le Floc’h, A, Allinne, J, Nagashima, K, et al. Allergy. 2020; 75: 1188– 1204
Induction of IgG(2) and IgG(4) B-cell memory following sublingual immunotherapy for ryegrass pollen allergy
Heeringa, JJ, McKenzie, CI, Varese, N, et al. Allergy. 2020; 75: 1121– 1132
Intranasal nanoemulsion vaccine confers long-lasting immunomodulation and sustained unresponsiveness in a murine model of milk allergy
O'Konek, JJ, Landers, JJ, Janczak, KW, et al. Allergy. 2020; 75: 872– 881
TGFβ1 mimetic peptide modulates immune response to grass pollen allergens in mice
Araujo, GR, Aglas, L, Vaz, ER, et al. Allergy. 2020; 75: 882– 891
Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection
Jarkvist, J, Salehi, C, Akin, C, Gülen, T. Allergy. 2020; 75: 169– 177
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Ariëns, LFM, van der Schaft, J, Bakker, DS, et al. Allergy. 2020; 75: 116– 126
Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs
Benito-Villalvilla, C, Soria, I, Pérez-Diego, M, Fernández-Caldas, E, Subiza, JL, Palomares, O. Allergy. 2020; 75: 648– 659
A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens
Huang, H-J, Curin, M, Banerjee, S, et al. Allergy. 2019; 74: 2461– 2478
Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
Rudulier, CD, Tonti, E, James, E, Kwok, WW, Larché, M. Allergy. 2019; 74: 2157– 2166
IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma
Russkamp, D, Aguilar-Pimentel, A, Alessandrini, F, et al. Allergy. 2019; 74: 1549– 1560
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Chapman, KR, Albers, FC, Chipps, B, et al. Allergy. 2019; 74: 1716– 1726
Variability of allergens in commercial fish extracts for skin prick testing
Ruethers, T, Taki, AC, Nugraha, R, et al. Allergy. 2019; 74: 1352– 1363
Chemically modified peanut extract shows increased safety while maintaining immunogenicity
van der Kleij, HPM, Warmenhoven, HJM, van Ree, R, et al.Allergy. 2019; 74: 986– 995
Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy
Boonpiyathad, T, Sokolowska, M, Morita, H, et al. Allergy. 2019; 74: 976– 985
Preventive sublingual immunotherapy with house dust mite extract modulates epitope diversity in pre-school children
Ponce, M, Schroeder, F, Bannert, C, et al. Allergy. 2019; 74: 780– 787
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
Jonstam, K, Swanson, BN, Mannent, LP, et al. Allergy. 2019; 74: 743– 752